Earnings Report /

Ibn Sina Pharmaceutical Industry Ltd: Annual FY21: Earnings surpassed expectation by c8%

  • EPS of the company stood at BDT 15.7 (NPAT BDT489mn) in FY21, implying c24% growth over BDT 12.6 (NPAT BDT393mn) in FY20

  • Q4 FY21 EPS stood at BDT 4.7 against BDT 2.9 in Q4 FY20, thus implying c59% earnings growth yoy

  • We reiterate Buy for IBNSIN with an updated TP of BDT 345.0 (ETR 30.2%)

Tanay Kumar Roy
Tanay Kumar Roy

Research Analyst

IDLC Securities
24 September 2021
Published by